Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Restructuring Costs: 2011-2016

Historic Restructuring Costs for Ligand Pharmaceuticals (LGND) over the last 6 years, with Dec 2016 value amounting to $1.0 million.

  • Ligand Pharmaceuticals' Restructuring Costs fell 27.78% to $169,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $1.0 million, marking a year-over-year increase of 1.18%. This contributed to the annual value of $1.0 million for FY2016, which is 1.18% up from last year.
  • According to the latest figures from FY2016, Ligand Pharmaceuticals' Restructuring Costs is $1.0 million, which was up 1.18% from $1.0 million recorded in FY2015.
  • Ligand Pharmaceuticals' 5-year Restructuring Costs high stood at $1.1 million for FY2014, and its period low was $560,000 during FY2013.
  • For the 3-year period, Ligand Pharmaceuticals' Restructuring Costs averaged around $1.0 million, with its median value being $1.0 million (2016).
  • Its Restructuring Costs has fluctuated over the past 5 years, first crashed by 45.21% in 2013, then soared by 93.57% in 2014.
  • Over the past 5 years, Ligand Pharmaceuticals' Restructuring Costs (Yearly) stood at $1.0 million in 2012, then crashed by 45.21% to $560,000 in 2013, then spiked by 93.57% to $1.1 million in 2014, then decreased by 5.90% to $1.0 million in 2015, then rose by 1.18% to $1.0 million in 2016.